Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alphatec HoldingsATEC +1.02%66 3-Year EBITDA Growth Rate is 53.60% as of Mar. 2026, which is 107% above its 10-year median of 25.95. GuruFocus rates ATEC with a GF Score™ of 66/100 and a GF Value™ of $15.47 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 691 Medical Devices & Instruments companies, Alphatec Holdings ranks better than 89.73% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 53.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 32.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Alphatec Holdings was 72.50% per year. The lowest was -95.50% per year. And the median was 25.95% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Alphatec Holdings 3-Year EBITDA Growth Rate Related Terms
ATEC vs CNMD, AORT, IRMD: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Alphatec Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alphatec Holdings 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Alphatec Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Alphatec Holdings's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 53.60% mean?
Alphatec Holdings (ATEC) has a 3-Year EBITDA Growth Rate of 53.60% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Alphatec Holdings and its competitors. This is 107% above median its historical median of 25.95. According to the industry distribution chart, Alphatec Holdings ranks #71 out of 691 companies in the Medical Devices & Instruments industry, placing it in the top 10.3%.
Is Alphatec Holdings' 3-Year EBITDA Growth Rate too high?
Alphatec Holdings' current 3-Year EBITDA Growth Rate of 53.60% is 107% above median its 10-year median of 25.95. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. Alphatec Holdings' value of 53.60% is 561.7% above this industry median. Based on the distribution chart, Alphatec Holdings ranks #71 out of 691 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Alphatec Holdings has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Alphatec Holdings' 3-Year EBITDA Growth Rate compare to CNMD and AORT?
According to the Medical Devices & Instruments industry distribution chart, Alphatec Holdings ranks #71 out of 691 companies for 3-Year EBITDA Growth Rate. This places Alphatec Holdings in the top 10% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.10. Alphatec Holdings' value of 53.60% is 561.7% above this benchmark. While the company's 10-year median is 25.95 vs. the industry median of 8.10, Alphatec Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alphatec Holdings's current 3-Year EBITDA Growth Rate of 53.60% is 561.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Alphatec Holdings and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alphatec Holdings's current 3-Year EBITDA Growth Rate is 53.60%, which is 107% above median its own 10-year median of 25.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alphatec Holdings stock overvalued right now?
Based on GuruFocus' analysis, Alphatec Holdings (ATEC) is currently considered Possible Value Trap. The stock's GF Value™ is $15.47, compared to a current price of $9.42 — trading 39.1% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 53.60%, which is 107% above median its 10-year median of 25.95 and 561.7% above the Medical Devices & Instruments industry median of 8.10. Alphatec Holdings' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Alphatec Holdings (ATEC), the current 3-Year EBITDA Growth Rate is 53.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alphatec Holdings (ATEC) Overvalued in 2026?
Based on GuruFocus' analysis, Alphatec Holdings stock appears to be undervalued.
The current stock price of $9.42 is trading 39.1% below its estimated GF Value™ of $15.47.
GuruFocus considers Alphatec Holdings to be Possible Value Trap.
Key valuation signals for ATEC:
3-Year EBITDA Growth Rate: 53.60% (107% above median its 10-year median of 25.95)
GF Value™: $15.47 vs. price of $9.42 (39.1% below fair value)
Industry Position: 561.7% above the Medical Devices & Instruments median (#71 of 691)
No single metric tells the full story. See the ATEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. Its procedural offerings are designed to address the underlying causes of spinal pathology by advancing the three fundamental objectives of spine surgery: (1) decompression of neural elements, (2) stabilization of spinal segments, and (3) restoration and maintenance of proper spinal alignment.
66GF Score
Get the complete analysis for ATEC
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATEC has been successfully added to your 
